Fiebersyndrome: Kinderwunsch und Schwangerschaft

Grundsätzlich gilt auch für Patientinnen mit autoinflammatorischen Erkrankungen derselbe Grundsatz wie bei anderen chronisch entzündlichen Erkrankungen: Vor einer Schwangerschaft (ideal: 6 Monate) sollten diese Patientinnen unter einer mit einer Schwangerschaft zu vereinbarenden Medikation in stabiler Remission sein. So ist das Risiko für Mutter und Kind möglichst gering zu halten.

• Literatur

• 1 Sohar E, Gafni J, Pras M. et al. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967; 43: 227-253
• 2 Mijatovic V, Hompes PG, Wouters MG. Familial Mediterranean fever and its implications for fertility and pregnancy. Eur J Obstet Gynecol Reprod Biol 2003; 108: 171-176
• 3 Ben-Chetrit E, Levy M. Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis 2003; 62: 916-919
• 4 Ehrenfeld M, Brzezinski A, Levy M. et al. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. Br J Obstet Gynaecol 1987; 94: 1186-1191
• 5 MontʼAlverne AR, Pereira RM, Yamakami LY. et al. Reduced ovarian reserve in patients with Takayasu arteritis. J Rheumatol 2014; 41: 2055-2059
• 6 Henes M, Froeschlin J, Taran FA. et al. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behcetʼs disease and spondyloarthritis on anti-Mullerian hormone levels. Rheumatology (Oxford) 2015; 54: 1709-1712
• 7 Lawrenz B, Henes J, Henes M. et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus 2011; 20: 1193-1197
• 8 MontʼAlverne AR, Yamakami LY, Goncalves CR. et al. Diminished ovarian reserve in Behcetʼs disease patients. Clin Rheumatol 2015; 34: 179-183
• 9 de Souza FH, da Silva CA, Yamakami LY. et al. Reduced ovarian reserve in patients with adult polymyositis. Clin Rheumatol 2015; 34: 1795-1799
• 10 Henes M, Rall K, Igney-Oertel A. et al. Anti-Müllerian hormone levels are not reduced in patients with adult autoinflammatory diseases compared to healthy controls. Scan J Rheumatol 2017; 46: 165-166
• 11 Sahin A, Karakus S, Durmaz Y. et al. Evaluation of ovarian reserve with anti-mullerian hormone in familial mediterranean fever. Int J Rheumatol 2015; 2015: 380354
• 12 Ben-Chetrit E, Backenroth R, Haimov-Kochman R. et al. Azoospermia in familial Mediterranean fever patients: the role of colchicine and amyloidosis. Ann Rheum Dis 1998; 57: 259-260
• 13 Haimov-Kochman R, Prus D, Ben-Chetrit E. Azoospermia due to testicular amyloidosis in a patient with familial Mediterranean fever. Hum Reprod 2001; 16: 1218-1220
• 14 Haimov-Kochman R, Ben-Chetrit E. The effect of colchicine treatment on sperm production and function: a review. Hum Reprod 1998; 13: 360-362
• 15 Yasar O, Iskender C, Kaymak O. et al. Retrospective evaluation of pregnancy outcomes in women with familial Mediterranean fever. J Matern Fetal Neonatal Med 2014; 27: 733-736
• 16 Ofir D, Levy A, Wiznitzer A. et al. Familial Mediterranean fever during pregnancy: an independent risk factor for preterm delivery. Eur J Obstet Gynecol Reprod Biol 2008; 141: 115-118
• 17 Ben-Chetrit E, Ben-Chetrit A, Berkun Y. et al. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified?. Arthritis Care Res (Hoboken) 2010; 62: 143-148
• 18 Amoura Z, Schermann JM, Wechsler B. et al. Transplacental passage of colchicine in familial Mediterranean fever. J Rheumatol 1994; 21: 383
• 19 Diav-Citrin O, Shechtman S, Schwartz V. et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol 2010; 203: 144.e1-144.e6
• 20 Rabinovitch O, Zemer D, Kukia E. et al. Colchicine treatment in conception and pregnancy: two hundred thirty-one pregnancies in patients with familial Mediterranean fever. Am J Reprod Immunol 1992; 28: 245-246
• 21 Berkenstadt M, Weisz B, Cuckle H. et al. Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever. Am J Obstet Gynecol 2005; 193: 1513-1516
• 22 Herscovici T, Merlob P, Stahl B. et al. Colchicine use during breastfeeding. Breastfeed Med 2015; 10: 92-95
• 23 McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006; 3: e297
• 24 Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010; 140: 784-790
• 25 Gerfaud-Valentin M, Maucort-Boulch D, Hot A. et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) 2014; 93: 91-99
• 26 Lequerre T, Quartier P, Rosellini D. et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67: 302-308
• 27 Pouchot J, Arlet JB. Biological treatment in adult-onset Stillʼs disease. Best Pract Res Clin Rheumatol 2012; 26: 477-487
• 28 Gerfaud-Valentin M, Hot A, Huissoud C. et al. Adult-onset Stillʼs disease and pregnancy: about ten cases and review of the literature. Rheumatol Int 2014; 34: 867-871
• 29 Le Loet X, Daragon A, Duval C. et al. Adult onset Stillʼs disease and pregnancy. J Rheumatol 1993; 20: 1158-1161
• 30 Mok MY, Lo Y, Leung PY. et al. Pregnancy outcome in patients with adult onset Stillʼs disease. J Rheumatol 2004; 31: 2307-2309
• 31 Yamamoto M, Tabeya T, Suzuki C. et al. Adult-onset Stillʼs disease in pregnancy. Mod Rheumatol 2012; 22: 163-165
• 32 Liozon E, Ly K, Aubard Y. et al. Intravenous immunoglobulins for adult Stillʼs disease and pregnancy. Rheumatology (Oxford) 1999; 38: 1024-1025
• 33 Vignes S, Wechsler B, Amoura Z. et al. Intravenous immunoglobulin in adult Stillʼs disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 1998; 16: 295-298
• 34 Fischer-Betz R, Specker C, Schneider M. Successful outcome of two pregnancies in patients with adult-onset Stillʼs disease treated with IL-1 receptor antagonist (anakinra). Clin Exp Rheumatol 2011; 29: 1021-1023
• 35 Izumi Y, Mori T, Matsuo M. et al. Leukocytapheresis (LCAP) for treating refractory adult-onset Stillʼs disease (AOSD). Mod Rheumatol 2012; 22: 483-487
• 36 Kanekura T, Terasaki K, Higashi Y. et al. Improvement of adult Stillʼs disease with granulocyte and monocyte adsorption apheresis. Clin Exp Dermatol 2004; 29: 410-412
• 37 Odai T, Isozaki T, Kasama T. et al. Therapeutic efficacy of leukocytapheresis in a pregnant woman with refractory adult-onset stillʼs disease. Intern Med 2015; 54: 2261-2266
• 38 Leslie KS, Lachmann HJ, Bruning E. et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006; 142: 1591-1597
• 39 Tran TA, Kone-Paut I, Marie I. et al. Muckle-Wells syndrome and male hypofertility: a case series. Semin Arthritis Rheum 2012; 42: 327-331
• 40 Chang Z, Spong CY, Jesus AA. et al. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheumatol 2014; 66: 3227-3232
• 41 ter Haar NM, Oswald M, Jeyaratnam J. et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015; 74: 1636-1644